【摘要】：目的系統(tǒng)評價尼妥珠單抗治療食管癌的有效性和安全性。方法檢索Medline、EMbase、Cochrane Library、Clinical Trials、中國生物醫(yī)學文獻數據庫、相關期刊論文、維普和萬方數據庫,收集尼妥珠單抗治療食管癌的臨床試驗,試驗組予以尼妥珠單抗聯(lián)合常規(guī)放化療/化療方案治療,對照組予以常規(guī)放化療/化療方案治療。用Rev Man 5.3對有效率、控制率、生存率和藥物不良反應發(fā)生率等主要指標進行Meta分析。結果共納入10項研究,共計535例患者。試驗組和對照組的有效率分別為79.84%和65.96%;1年生存率分別為83.76%和67.13%;3年生存率分別為30.00%和14.29%;1年無進展生存率分別為85.26%和69.47%,差異均有統(tǒng)計學意義(均P0.05)。試驗組和對照組的控制率分別為90.71%和79.88%;血液學毒性發(fā)生率分別為52.17%和50.95%;胃腸道反應發(fā)生率分別為31.90%和38.79%;放射性食管炎發(fā)生率分別為41.15%和36.17%;放射性肺炎發(fā)生率分別為15.82%和19.02%,差異均無統(tǒng)計學意義(均P0.05)。結論尼妥珠單抗對提高食管癌患者有效率并延長生存期有優(yōu)勢,且未增加藥物不良反應的發(fā)生,可推薦聯(lián)合放化療/放療用于食管癌患者治療。
[Abstract]:Objective to evaluate the efficacy and safety of neytozumab in the treatment of esophageal carcinoma. Methods Medline,EMbase,Cochrane Library,Clinical Trials, Chinese Biomedical Literature Database, Chinese Journal Full-text Database, Weip and Wanfang databases were searched, and the clinical trials of Niytozumab in the treatment of esophageal carcinoma were collected. The experimental group was treated with niytozumab combined with conventional radiotherapy and chemotherapy, while the control group was treated with routine chemotherapy / radiotherapy. The effective rate, control rate, survival rate and incidence rate of adverse drug reactions were analyzed by Meta with Rev Man 5.3. Results A total of 535 patients were included in 10 studies. The effective rates of the two groups were 79.84% and 65.96%, the 1-year survival rates were 83.76% and 67.13%, the 3-year survival rates were 30.00% and 14.29%, respectively. The 1 year progression-free survival rate was 85.26% and 69.47%, respectively, and the difference was statistically significant (P0.05). The control rates of the test group and the control group were 90.71% and 79.88%, the incidence of hematological toxicity were 52.17% and 50.955%, the incidence of gastrointestinal reaction were 31.90% and 38.79%, respectively. The incidence of radiation esophagitis was 41.15% and 36.17%, and the incidence of radiation pneumonia was 15.82% and 19.02%, respectively. The difference was not significant (P0.05). Conclusion Niytozumab has advantages in improving the effective rate and prolonging the survival time of esophageal cancer patients, and does not increase the incidence of adverse drug reactions. It is recommended that combined radiotherapy and chemotherapy / radiotherapy should be used in the treatment of esophageal cancer patients.
【作者單位】： 首都醫(yī)科大學附屬北京世紀壇醫(yī)院藥劑科;北京大學藥學院藥事管理與臨床藥學系;
【分類號】：R735.1

【相似文獻】

相關期刊論文 前5條

1 譚永才;程濤;;碘(~(131)I)美妥昔單抗治療AFP升高1例[J];廣東醫(yī)學;2009年10期

2 劉玉琳;王軍;;細胞免疫在單抗治療腫瘤中的作用研究進展[J];現(xiàn)代免疫學;2011年01期

3 阮新建;王飛;宋飛翔;賈得前;;貝伐珠單抗治療惡性腫瘤的相關不良反應及處理[J];中國醫(yī)藥導刊;2013年11期

4 倪鳳明;姜新;馬利新;黃祥;侯威;陳祥;曲雅勤;;放療聯(lián)合尼妥珠單抗治療晚期復發(fā)直腸癌的療效[J];中國老年學雜志;2014年07期

5 ;[J];;年期

相關重要報紙文章 前1條

1 美國食品藥品管理局 歐盟藥品管理局網站;貝伐珠單抗治療乳腺癌風險評價研究引發(fā)廣泛關注[N];中國醫(yī)藥報;2011年

，

本文編號：2395082